- Current report filing (8-K)
November 12 2010 - 11:49AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): November 12, 2010
SHENGTAI
PHARMACEUTICAL, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
000-51312
|
|
54-2155579
|
(State
or other jurisdiction of incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
Changda
Road East
Development
District, Changle County
Shandong,
262400
The
People’s Republic of China
(Address
of principal executive offices, including zip code)
(86)
536-6295802
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.03
Amendments to
Articles of Incorporation or Bylaws; Change in Fiscal Year
Effective
on November 9, 2010, Shengtai Pharmaceutical, Inc., the “Company”, effected a
1-for-2 reverse stock split of its issued and outstanding shares of Common
Stock, and reduced the number of its authorized shares of Common Stock and
Preferred Stock by the same reverse stock split ratio. The reverse
stock split and the reduction of the number of authorized shares of Common Stock
and Preferred Stock were authorized by the stockholders of the Company at the
annual general meeting of stockholders held on October 26, 2010 and by the Board
of Directors of the Company on November 3, 2010. Upon effectiveness
of the reverses stock split, the outstanding and issued shares shall be
approximately 9,584,903 shares, before rounding up of fractional
shares. The authorized number of shares of Common Stock is reduced
from 100,000,000 to 50,000,000, and the authorized number of shares of Preferred
Stock is reduced from 5,000,000 to 2,500,000.
The
reverse stock split and the reduction of the authorized number of shares of
Common Stock and Preferred Stock are reflected in the Certificate of Amendment
attached herein, filed with the Delaware Secretary of State on November 9,
2010.
Item
8.01
Other
Events
The
Company new CUSIP number is 823214200.
Item
9.01
Financial Statements
and Exhibits
(d) Exhibits
Exhibit
No
|
Description
|
|
|
99.1
|
Certificate
of Amendment filed with the Delaware Secretary of State on November 9,
2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
Company has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
SHENGTAI
PHARMACEUTICAL, INC.
|
|
|
|
|
Dated:
November 12, 2010
|
|
|
By:
/s/ Qingtai
Liu
|
|
Name:
Qingtai Liu
|
|
Title:
Chief Executive Officer
|
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From May 2024 to Jun 2024
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Jun 2023 to Jun 2024